Find Neomycin Sulfate Tablet, Intestinal Infection, Colonic Operation on Industry Directory, Reliable Manufacturer/Supplier/Factory from China.

Inquiry Basket (0)
Home > Products > Gastro-Intestinals Drug > Guyenne Omeprazole Delayed Release, Acid Reducer Injection 40 Mg

Guyenne Omeprazole Delayed Release, Acid Reducer Injection 40 Mg

Basic Info

Model No.:  DAWAODR0001

Product Description

Model NO.: DAWAODR0001 Usage Mode: For external use State: Solid Type: Biological Products Name: Omeprazole for Injection OEM: Acceptable MOQ: 1 Box Specification: 40mg HS Code: 29333990 Application: Internal Medicine Suitable for: Elderly, Children, Adult Shape: Powder Pharmaceutical Technology: Chemical Synthesis Administration Route: I.V Quality Standard: GMP Trademark: GUYENNE Origin: France General Medicine Omeprazole 20mg Injection For Gastrohelcosis And Stomach Acid 
Specification 40mg
Package 1vial+1amp/box

Guyenne Omeprazole Delayed Release, Acid Reducer Injection 40 Mg
 Omeprazole, sold under the brand names Prilosec and Losec among others, is a medication used in the treatment of gastroesophageal reflux disease, peptic ulcer disease, and Zollinger-Ellison syndrome.[1] It is also used to prevent upper gastrointestinal bleeding in people who are at high risk.[1] It can taken by mouth or injected into a vein. Common side effects include nausea, vomiting, headaches, and increased intestinal gas. Serious side effects may include Clostridium difficile colitis, an increased risk of pneumonia, an increased risk of bone fractures, and the potential of masking stomach cancer. It is unclear if it is safe for use in pregnancy. Omeprazole is a proton pump inhibitor and as such blocks the release of stomach acid.

Medical uses
Omeprazole can be used in the treatment of gastroesophageal reflux disease (GERD), peptic ulcers, erosive esophagitis, and Zollinger-Ellison syndrome.

Peptic ulcers

Guyenne Omeprazole Delayed Release, Acid Reducer Injection 40 Mg

Pregnancy and breast-feeding
Epidemiological data do not show an increased risk of major birth defects after maternal use of omeprazole during pregnancy. No clinical trials have deeply evaluated the potential consequences of the use of omeprazole in breastfeeding. However, the pharmacokinetics of omeprazole molecule strongly suggest the safety of omeprazole use during breastfeeding: Omeprazole has a high plasma protein binding rate (95%), indicating that little amount of drug is transferred to the milk duct during breast milk formation. Omeprazole needs to be administrated in an enteric-coated formulation due to its rapid degradation in the acidic conditions of the stomach. This suggests that most of the free molecules ingested by the infant are likely degraded before being absorbed. Omeprazole at normal doses is likely safe during breastfeeding.

Contact us if you need more details on Omeprazole. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Prilosec、Losec. If these products fail to match your need, please contact us and we would like to provide relevant information.

Product Categories : Gastro-Intestinals Drug